Ropivacaine (rINN) is a local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer. Ropivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Naropin. Ropivacaine was developed after bupivacaine was noted to be associated with cardiac arrest, particularly in pregnant women. Ropivacaine was found to have less cardiotoxicity than bupivacaine in animal models.Identification:1. Positive reaction2. IR meets USP34 requirementAbsorbance:A405: ≤ 0.03A436: ≤ 0.025pH: 4.5-6.0Optical Isomers: ≤ 0.5%Water: 5.0-6.0%Heavy Metals: ≤ 0.001%Optical Rotation: -215 to -255°2,6-Dimethylaniline: ≤ 0.001%Related Substances:Bupivacaine: ≤ 0.2%Single Impurities: ≤ 0.1%Total Impurities: ≤ 0.5%Solubility: Methanol, WaterConforms to USP34
